Recently, GLP-1 injections such as Wegovy, Mounjaro, and Saxenda — used to treat obesity and diabetes — have become a major topic of conversation. In clinics and online communities, questions like these frequently come up.
“I started Wegovy and I’m losing weight, but my migraines have gotten worse. Should I stop taking it?”
“On the other hand, since starting Mounjaro, my persistent headaches have completely disappeared. Why is that?”
Today, I’ve written this post to clearly answer these confusing questions from patients.
Why Diet Injections (Wegovy & Mounjaro) Can Both Trigger and Relieve Your Headaches 💉🧠
Let’s explore the surprising and complex relationship between GLP-1 injections (Wegovy, Mounjaro, Saxenda, etc.) and migraines — a topic that is taking the world by storm.
Some people find their headaches completely resolved after starting these medications, while others experience excruciating head pain early on. Why do such opposite reactions occur? Let me explain in simple terms based on the latest neuroscience and metabolic medicine.
💡 1. The Positive Effects: How Can a Weight-Loss Drug Treat Headaches?
In the medical world, migraine is viewed not just as pain, but as “the brain’s battery running out (energy deficiency), forcing the brain to shut down its systems.”
GLP-1 injections dramatically improve this ‘brain battery efficiency.’
- Reduced Intracranial Pressure: Inside our brain is cerebrospinal fluid that cushions and supports the brain. GLP-1 injections reduce the production of this fluid, rapidly lowering the pressure inside the brain and relieving headaches.
- Optimized Brain Energy: They help brain cells use energy far more efficiently and reduce inflammation in the brain that causes pain.
- Weight Loss Synergy: When we gain weight, fat cells release inflammatory substances that worsen headaches. As weight decreases, the frequency and intensity of migraines naturally drop as well.
🌋 2. The Paradoxical Side Effect: Why Does It Hurt More at First?
If this medication is so beneficial, why do headaches worsen when first starting or increasing the dose? There are 3 hidden pitfalls.
- Gastrointestinal Bottleneck (Delayed Drug Absorption): GLP-1 injections slow gastric emptying to create a feeling of fullness. The problem is that headache medications you take are also trapped in the stomach and cannot move to the intestines. Since the medication isn’t absorbed, you end up in a situation where “my usual headache pill just doesn’t work anymore!”
- Rapid Blood Sugar Drop and Fasting State: As appetite drops sharply, you may unintentionally stop eating and drinking. From the brain’s perspective, this is an extreme stressful situation — like cutting off its fuel supply — which can trigger a migraine attack.
- Temporary Vasodilation: During the drug adaptation period, temporary blood vessel dilation may cause throbbing headaches.
📈 3. Smart Strategies for Headache Patients (Don’t Give Up!)
The initial worsening of headaches is usually a temporary phenomenon during the 2–4 week adaptation period. If you can weather the storm, you’ll be rewarded with significantly fewer headaches in the long run.
How should you manage it?
- Change the form of your headache medication: Instead of oral tablets, switch to injectable headache medications (such as sumatriptan auto-injectors) or nasal spray formulations that bypass the stomach and are absorbed directly. The challenge in Korea is that some options widely recommended abroad — such as nasal sprays or self-injectable headache medications — may not be readily available. Today, we’ll focus on solutions tailored to Korea’s realistic healthcare environment using newer CGRP therapies.
Solution: A Paradigm Shift to ‘Novel CGRP-Targeted Therapies’
If you are suffering because conventional oral tablets are not being absorbed, the answer is to switch to the latest medications that either prevent headaches from occurring in the first place or overcome the gastrointestinal absorption problem. See our detailed guide on Emgality & Ajovy CGRP antibodies for the full picture.
① Monthly CGRP Antibody Injections ‘Once a Month’ (The Core of Prevention)
- Types: Ajovy, Emgality, etc.
- Feature: These medications are not taken when a headache strikes — they are preventive injections given once a month.
- Advantages: As subcutaneous injections, they are absorbed directly into the bloodstream regardless of gastric condition (food retention). Even when the stomach is slowed by Wegovy/Mounjaro, the protective shield remains solid. They block the pain switch from activating even when the brain enters an ‘Energy Mismatch’ state.
② Oral Next-Generation CGRP Therapies — the ‘Gepants’ Class
- Types: Aquipta, Nurtec, etc.
- Feature: These are the most cutting-edge oral tablets recently introduced or being introduced in Korea.
- Advantages: Fewer side effects than older triptan-class drugs, and excellent efficacy for both prevention and acute treatment. In particular, medications like ‘Aquipta,’ taken daily as a preventive, powerfully help stabilize the brain sensitivity fluctuations caused by GLP-1 injections.
Additional Practical Tips
- Increase the dose slowly — very slowly: Give your brain time to adapt by raising the injection dose much more gradually than a standard weight-loss schedule.
- ‘Water’ and ‘Protein’ are medicine: Even when appetite is low, replenish fluids with electrolyte drinks and consume small amounts of protein regularly to keep your brain from running out of energy.
📌 Key Takeaway: If your headaches worsen while on Wegovy or Mounjaro, do not abruptly stop the medication. Stay well-hydrated, eat regularly, and work with your neurologist to adjust your headache medication formulation. Once you push through, the brain’s energy will stabilize and a more comfortable phase will arrive.
Related Reading
- [Revolution in Migraine Treatment] Emgality & Ajovy (deep dive on CGRP antibodies)
- What Headache Medications Are Available?
- Magnesium and Migraine: The Evidence-Based Supplementation Guide
- Do You Have a Headache Because of Indigestion? (gastric ↔ headache connection)
📚 References
- IIH: Pressure Trial (2023): A key clinical study from the University of Birmingham published in the journal Brain and others, demonstrating that GLP-1 agonists (Exenatide) suppress cerebrospinal fluid secretion, rapidly reduce intracranial pressure, and improve idiopathic intracranial hypertension (IIH) and related headaches.
- Mitochondrial Energy Mismatch Theory: The core neurological theory that the root cause of migraine is an energy metabolism imbalance in the brain (Borkum, J.M. and multiple combined studies).
- Latest Clinical Reports (2024–2025): Clinical pharmacological evidence and guidelines showing that delayed gastric emptying caused by obesity/diabetes medications inhibits the absorption of oral acute-phase migraine medications.
- AHS (American Headache Society) 2024 Update: The latest guidelines recommending CGRP-targeted therapies as first-line preventive treatments.
- Clinical Pharmacokinetics (2024): Analysis of the impact of GLP-1 receptor agonist-induced delayed gastric emptying on oral drug absorption rate (Tmax).
- International Headache Congress (2023–2025): Synergy effects and safety data from combining obesity treatment with CGRP preventive therapy.